tiprankstipranks
Advertisement
Advertisement

AMGN Stock Latest News

Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
Company AnnouncementsAmgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
4d ago
AMGN
Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
PremiumCompany Announcements
Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
5d ago
AMGN
Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations
PremiumCompany Announcements
Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations
5d ago
AMGN
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data
PremiumThe Fly
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data
6d ago
AMGN
IONS
Amgen price target raised to $420 from $400 at UBS
PremiumThe Fly
Amgen price target raised to $420 from $400 at UBS
8d ago
AMGN
Amgen price target raised to $312 from $307 at BofA
PremiumThe FlyAmgen price target raised to $312 from $307 at BofA
8d ago
AMGN
Amgen price target raised to $343 from $340 at Guggenheim
Premium
The Fly
Amgen price target raised to $343 from $340 at Guggenheim
8d ago
AMGN
Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
Premium
Ratings
Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
8d ago
AMGN
Amgen price target lowered to $333 from $340 at Morgan Stanley
PremiumThe Fly
Amgen price target lowered to $333 from $340 at Morgan Stanley
13d ago
AMGN
Amgen price target raised to $340 from $327 at Truist
PremiumThe Fly
Amgen price target raised to $340 from $327 at Truist
14d ago
AMGN
Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line
PremiumCompany Announcements
Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line
19d ago
AMGN
Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race
PremiumCompany Announcements
Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race
20d ago
AMGN
Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study
PremiumCompany AnnouncementsAmgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study
20d ago
AMGN
CodeBreaK 100: Amgen’s KRAS Trial Update and What It Means for AMGN Investors
Premium
Company Announcements
CodeBreaK 100: Amgen’s KRAS Trial Update and What It Means for AMGN Investors
21d ago
AMGN
Trial used to approve Amgen’s Tavneos retracted from NEJM
Premium
The Fly
Trial used to approve Amgen’s Tavneos retracted from NEJM
22d ago
AMGN
Why Schwab U.S. Dividend Equity ETF (SCHD) Could Jump 15%, According to AI
PremiumMarket News
Why Schwab U.S. Dividend Equity ETF (SCHD) Could Jump 15%, According to AI
25d ago
MRK
UNH
Midday Fly By: Micron reports blowout Q3, Apple boosts MacBook prices
PremiumThe Fly
Midday Fly By: Micron reports blowout Q3, Apple boosts MacBook prices
26d ago
BB
GS
FDA works to pull Amgen’s Tavneos off the market, Bloomberg says
PremiumThe Fly
FDA works to pull Amgen’s Tavneos off the market, Bloomberg says
26d ago
AMGN
Amgen price target raised to $303 from $295 at Mizuho
PremiumThe Fly
Amgen price target raised to $303 from $295 at Mizuho
1M ago
AMGN
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial
PremiumCompany AnnouncementsAmgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial
1M ago
AMGN
Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
Premium
Company Announcements
Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
1M ago
AMGN
Amgen price target raised to $340 from $332 at Morgan Stanley
Premium
The Fly
Amgen price target raised to $340 from $332 at Morgan Stanley
1M ago
AMGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >